We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

220 hedge funds and large institutions have $2.55B invested in Agios Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 68 increasing their positions, 69 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

24% more capital invested

Capital invested by funds: $2.05B → $2.55B (+$494M)

23% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 35

3% more funds holding

Funds holding: 214 → 220 (+6)

2.77% more ownership

Funds ownership: 106.52% → 109.29% (+2.8%)

9% more call options, than puts

Call options by funds: $85.2M | Put options by funds: $78.2M

1% less repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 69

Holders
220
Holders Change
+6
Holders Change %
+2.8%
% of All Funds
2.89%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
43
Increased
68
Reduced
69
Closed
35
Calls
$85.2M
Puts
$78.2M
Net Calls
+$7.06M
Net Calls Change
+$4.49M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$77.1M
2
PBA
Paradigm Biocapital Advisors
New York
+$57.6M
3
TCM
TCG Crossover Management
California
+$27.6M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$18.6M
5
EAM
Erste Asset Management
Austria
+$16.5M

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$31.8M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$23.2M
3
Citadel Advisors
Citadel Advisors
Florida
-$22.2M
4
O
OrbiMed
New York
-$18.6M
5
Marshall Wace
Marshall Wace
United Kingdom
-$17.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
51
Peregrine Capital Management
Minnesota
$6.54M +$6.13M +162,905 New
Allianz Asset Management
52
Allianz Asset Management
Germany
$5.89M +$291K +7,745 +6%
Alyeska Investment Group
53
Alyeska Investment Group
Illinois
$5.88M +$5.51M +146,514 New
American Century Companies
54
American Century Companies
Missouri
$5.83M +$657K +17,474 +14%
PSC
55
Patient Square Capital
California
$5.37M -$222K -5,905 -4%
TD Asset Management
56
TD Asset Management
Ontario, Canada
$5.15M -$1.5M -39,900 -24%
VPC
57
Vestal Point Capital
New York
$5.1M +$4.78M +127,000 New
IC
58
Ikarian Capital
Texas
$5.1M +$4.78M +126,979 New
Invesco
59
Invesco
Georgia
$5.1M +$540K +14,359 +13%
Hudson Bay Capital Management
60
Hudson Bay Capital Management
Connecticut
$4.92M -$282K -7,500 -6%
N
61
Nuveen
North Carolina
$4.8M – – –
UBS AM
62
UBS AM
Illinois
$4.29M -$4.16M -110,527 -51%
Swiss National Bank
63
Swiss National Bank
Switzerland
$4.28M -$105K -2,800 -3%
PHP
64
Parkman Healthcare Partners
Connecticut
$4.03M +$3.78M +100,380 New
NCM
65
Nantahala Capital Management
Connecticut
$4.01M +$3.76M +100,000 New
Prudential Financial
66
Prudential Financial
New Jersey
$3.94M -$2.26M -60,120 -38%
Manulife (Manufacturers Life Insurance)
67
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3.85M -$1.36M -36,071 -27%
AQR Capital Management
68
AQR Capital Management
Connecticut
$3.61M -$198K -5,261 -5%
JF
69
Jump Financial
Illinois
$3.53M +$3.31M +87,900 New
RhumbLine Advisers
70
RhumbLine Advisers
Massachusetts
$3.52M -$82K -2,179 -2%
First Trust Advisors
71
First Trust Advisors
Illinois
$2.99M +$1.43M +38,002 +104%
WP
72
Woodline Partners
California
$2.97M -$5.98M -159,072 -68%
Universal-Beteiligungs- und Servicegesellschaft
73
Universal-Beteiligungs- und Servicegesellschaft
Germany
$2.86M +$599K +15,929 +29%
Rafferty Asset Management
74
Rafferty Asset Management
New York
$2.74M +$708K +18,817 +38%
Assenagon Asset Management
75
Assenagon Asset Management
Luxembourg
$2.7M +$2.53M +67,153 New
1 2
3
4 5

AGIO Hedge Fund Activity: Q3 2025 in Review

220 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2025, worth a combined $2.55B — up 24% from $2.05B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new AGIO positions and 35 closed out — a net gain of 8 holders — while 68 added to existing stakes and 69 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $77.1M. The largest seller was JP Morgan Chase, cutting an estimated $31.8M.

  • 220 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2025, up from 214 in Q2 2025.
  • Funds reported $2.55B of Agios Pharmaceuticals stock for Q3 2025, up 24% quarter-over-quarter.
  • 43 funds opened new Agios Pharmaceuticals positions in Q3 2025 and 35 closed out, a net change of +8 holders.
  • The largest Agios Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $77.1M added.
  • The largest Agios Pharmaceuticals seller in Q3 2025 was JP Morgan Chase, an estimated $31.8M sold.

Based on aggregated 13F filings for Q3 2025.